Closed abdomen hyperthermic intraperitoneal chemotherapy with paclitaxel for advanced epithelial ovarian cancer - Hipecovario

Pedro Villarejo Campos(Hospital Universitario Ciudad Real)0 个研究点开始时间: 2012年2月22日最近更新: 2012年12月3日

试验速览

暂无简介。

•-Women over 18 years with histologically confirmed epithelial ovarian cancer stage II / III / IV (FIGO staging) or tumoral recurrences.
•-Complete debulking / optimal: Index CC0/CC1 cytoreduction (residual tumor size after surgery, no visible (CC0) or less than 0.25 cm (CC1))
•-No extra-abdominal tumor disease
•-Absence of heart failure, kidney or liver.
•-The treatment should be scheduled at least 1 month after the last administration of systemic chemotherapy.
•-Women have given their consent to participate in the study.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 79
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 10

•-Patients who have unresectable peritoneal carcinomatosis or those who can not complete optimal cytoreduction.
•-Extrabdominales metastases or unresectable liver metastases or involve a major hepatectomy what conditions a limited hepatic reserve.
•-Presence of other malignant tumor disease.
•-Multisegmental complete bowel obstruction.
•-Active infection or other condition that incapacitate for treatment according to the protocol proposed.
•-No specific acceptance of informed consent for this treatment.

发起方

Pedro Villarejo Campos(Hospital Universitario Ciudad Real)